ATHLONE, Ireland, May 7, 2015 (GLOBE NEWSWIRE) — Innocoll AG (Nasdaq:INNL) (the “Company”), a global, commercial-stage, specialty pharmaceutical company that develops and manufactures a range of pharmaceutical products and medical devices using its proprietary collagen-based technologies, today announced that it will report first quarter financial results before the open of U.S. financial markets on May 14, 2015. Innocoll management will host a webcast and conference call at 8:30 a.m. EDT that day to discuss the financial results and provide a corporate update.
The live call may be accessed by dialing 877-407-4018 for domestic callers and 201-689-8471 for international callers. A live webcast of the call will be available online from the investor relations section of the company website at www.innocollinc.com and will be archived there for 90 days. A telephone replay of the call will be available until midnight EDT on May 17, 2015 by dialing 877-870-5176 for domestic callers or 858-384-5517 for international callers and entering the conference code: 13608017.
About Innocoll AG
Innocoll is a global, commercial-stage, specialty pharmaceutical company. The Company develops and manufactures a range of pharmaceutical products and medical devices using its proprietary collagen-based technologies. The Company’s late stage product pipeline is focused on addressing a number of large unmet medical needs, including: XaraColl® for the treatment of post-operative pain; Cogenzia® for the adjuvant treatment of diabetic foot infections; and CollaGUARD®, a barrier for the prevention of post-surgical adhesions. The Company’s approved products include: CollaGUARD(Ex-US), Collatamp® G, Septocoll®, RegenePro®, Collieva®, CollaCare®, Collexa®, and Zorpreva™, which are sold through strategic partnerships with various partners including Takeda, Biomet, and EUSA Pharma. All of the Company’s products are made using Type 1 collagen and are manufactured in-house at its facility in Saal, Germany. CollaRx®, Collatamp®, CollaGUARD®, Collieva®, CollaCare®, Collexa®, Cogenzia® LidoColl®, LiquiColl®, Septocoll®, and XaraColl® are registered trademarks, and CollaPress™, DermaSil™, Durieva™, and Zorpreva™ are trademarks of the Company.
Executive Vice President Business Development
and Corporate Affairs
Russo Partners, LLC
Robert E. Flamm, Ph.D.